MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($7.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MIRA net asset quality score to measure how much of total assets are equity-financed.
MIRA Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore MIRA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Creative Realities Inc
NASDAQ:CREX
|
-0.042x |
|
Mabion S.A.
WAR:MAB
|
-0.308x |
|
Tongyang Pile Inc
KQ:228340
|
0.000x |
|
Itama Ranoraya
JK:IRRA
|
-0.486x |
|
Avante Logixx Inc
V:XX
|
0.072x |
|
Symphony Life Bhd
KLSE:1538
|
-0.004x |
|
STOCK3 AG NA O.N.
XETRA:BOG
|
N/A |
|
Compal Broadband Networks Inc
TW:6674
|
-0.089x |
Annual Cash Flow Conversion Efficiency for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see MIRA Pharmaceuticals, Inc. Common Stock (MIRA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.20 Million | $-5.56 Million | -2.528x | -143.97% |
| 2023-12-31 | $4.37 Million | $-4.53 Million | -1.036x | -111.02% |
| 2022-12-31 | $-596.23K | $-5.60 Million | 9.400x | +1644.70% |
| 2021-12-31 | $2.26 Million | $-1.38 Million | -0.609x | -160.86% |
| 2020-12-31 | $-67.99K | $-67.99K | 1.000x | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more